Beximco Pharma has already applied to the US authorities for clearance to export several drugs to the American market
Singapore: The US Food and Drug Administration has approved the factories of Bangladeshi pharmaceutical majors Square and Beximco pharmaceuticals. This approval will make these companies eligible to export drugs to the US if the FDA clears their drugs list.
In a recent media release, Square pharmaceuticals said the FDA authorities in their recent assessment report, stated that Square met the current Good Manufacturing Practice (GMP) norms.
Beximco Pharmaceuticals in a statement said the FDA representatives visited its Tongi plant to assess oral solid doses facility also in January. The US drug authority's establishment inspection report has formally approved the factory.
Mr Nazmul Hasan, MD, Beximco pharmaceuticals, said, ""This is a great achievement for the pharmaceutical industry of Bangladesh. It creates opportunities for drug exports to the US. Also, getting approval from the US is a matter of pride since they are very strict on parameters and quality."
Beximco has approval from the authorities of the European Union, Australia, Canada, Taiwan and Brazil, among others, while Square pharmaceuticals currently exports drugs to 39 countries including the UK and Australia.
